ASC-话题@MedSci

#ASC#

1352篇内容 | 3990人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1939200, encodeId=c3bf1939200e3, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, objectType=article, longId=212408, objectId=4ea821240891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea821240891, replyNumber=0, likeNumber=101, createdTime=2021-12-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea821240891, moduleTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea821240891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939174, encodeId=24e619391e4b4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）, objectType=article, longId=211913, objectId=94fc21191398, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94fc21191398, replyNumber=0, likeNumber=86, createdTime=2022-03-11, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94fc21191398, moduleTitle=ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94fc21191398)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939172, encodeId=955919391e278, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021 :摘要概览与展望8 | 乳腺癌研究概览（男性乳腺癌专栏）, objectType=article, longId=211897, objectId=c66a21189e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66a21189e21, replyNumber=0, likeNumber=55, createdTime=2021-11-25, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66a21189e21, moduleTitle=ASCO 2021 :摘要概览与展望8 | 乳腺癌研究概览（男性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66a21189e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939196, encodeId=4b2e193919624, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021:转移性乳腺癌专场口头摘要概览, objectType=article, longId=212361, objectId=d2f0212361ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2f0212361ad, replyNumber=0, likeNumber=95, createdTime=2021-07-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2f0212361ad, moduleTitle=ASCO 2021:转移性乳腺癌专场口头摘要概览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2f0212361ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939148, encodeId=30de19391484b, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, objectType=article, longId=207272, objectId=f72f20e272b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72f20e272b6, replyNumber=0, likeNumber=154, createdTime=2021-08-25, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72f20e272b6, moduleTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72f20e272b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939198, encodeId=cd67193919873, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：免疫治疗新进展！中国智造替雷利珠单抗多项研究成果亮相, objectType=article, longId=212374, objectId=cbd22123e43e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbd22123e43e, replyNumber=0, likeNumber=113, createdTime=2021-06-18, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbd22123e43e, moduleTitle=ASCO 2021：免疫治疗新进展！中国智造替雷利珠单抗多项研究成果亮相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbd22123e43e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939181, encodeId=360b193918120, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望15 |乳腺癌研究概览（ER阳性乳腺癌专栏）, objectType=article, longId=212109, objectId=017e212109d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=017e212109d1, replyNumber=0, likeNumber=83, createdTime=2022-05-03, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017e212109d1, moduleTitle=ASCO 2021：摘要概览与展望15 |乳腺癌研究概览（ER阳性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=017e212109d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939175, encodeId=95e219391e52a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=2021ASCO| 第57届美国临床肿瘤学会年会在线开幕！, objectType=article, longId=211919, objectId=eb5a211919ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb5a211919ea, replyNumber=0, likeNumber=14, createdTime=2021-12-09, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb5a211919ea, moduleTitle=2021ASCO| 第57届美国临床肿瘤学会年会在线开幕！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb5a211919ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939162, encodeId=0d891939162c9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：天境生物公布其CD73抗体的1期临床研究成果，初步显示疗效信号, objectType=article, longId=211620, objectId=c7db21162029, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7db21162029, replyNumber=0, likeNumber=88, createdTime=2021-08-08, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7db21162029, moduleTitle=ASCO 2021：天境生物公布其CD73抗体的1期临床研究成果，初步显示疗效信号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7db21162029)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939117, encodeId=f95f193911ed9, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=Cardiovasc Intervent Radiol：使用支架进行腹腔镜结肠手术的肠吻合术可降低肠吻合时间, objectType=article, longId=203303, objectId=480e20330367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=480e20330367, replyNumber=0, likeNumber=81, createdTime=2021-10-09, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=480e20330367, moduleTitle=Cardiovasc Intervent Radiol：使用支架进行腹腔镜结肠手术的肠吻合术可降低肠吻合时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=480e20330367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939187, encodeId=6bad193918ee1, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）, objectType=article, longId=212244, objectId=5e4321224412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e4321224412, replyNumber=0, likeNumber=69, createdTime=2021-11-16, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e4321224412, moduleTitle=ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e4321224412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939199, encodeId=cfb8193919965, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：皮肤癌免疫疗法新进展, objectType=article, longId=212405, objectId=c84d21240500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84d21240500, replyNumber=0, likeNumber=101, createdTime=2022-02-17, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84d21240500, moduleTitle=ASCO 2021：皮肤癌免疫疗法新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84d21240500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939121, encodeId=e5061939121fd, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=J Vasc Interv Radiol：两年研究结果表明DCB血管成形术对AVFs长期安全且有效, objectType=article, longId=203453, objectId=c41020345368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41020345368, replyNumber=0, likeNumber=70, createdTime=2020-12-19, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41020345368, moduleTitle=J Vasc Interv Radiol：两年研究结果表明DCB血管成形术对AVFs长期安全且有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c41020345368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939225, encodeId=c70c193922550, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=BMC Cardiovascular Disorders：当一根长针扎进心脏 1 个月以上，人还活着！怎么取出针？——BMC期刊病例报道, objectType=article, longId=213369, objectId=76d8213369c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76d8213369c8, replyNumber=0, likeNumber=92, createdTime=2021-12-24, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76d8213369c8, moduleTitle=BMC Cardiovascular Disorders：当一根长针扎进心脏 1 个月以上，人还活着！怎么取出针？——BMC期刊病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76d8213369c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939215, encodeId=aa7e19392154d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, objectType=article, longId=212499, objectId=bef02124990d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bef02124990d, replyNumber=0, likeNumber=75, createdTime=2021-10-05, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bef02124990d, moduleTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bef02124990d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939192, encodeId=1cbe193919230, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：非小细胞肺癌专场--口头报告(01), objectType=article, longId=212342, objectId=b1b821234205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b821234205, replyNumber=0, likeNumber=70, createdTime=2022-05-22, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b821234205, moduleTitle=ASCO 2021：非小细胞肺癌专场--口头报告(01), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1b821234205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939218, encodeId=5f5f19392182d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021: 神经肿瘤综述（上）, objectType=article, longId=212502, objectId=040e212502e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040e212502e7, replyNumber=0, likeNumber=67, createdTime=2022-01-23, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040e212502e7, moduleTitle=ASCO 2021: 神经肿瘤综述（上）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=040e212502e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939135, encodeId=bc2b19391359d, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO GU 2021：Lu-177放射新疗法照亮前列腺癌放疗之路, objectType=article, longId=207174, objectId=400020e174d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=400020e174d4, replyNumber=0, likeNumber=68, createdTime=2021-08-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=400020e174d4, moduleTitle=ASCO GU 2021：Lu-177放射新疗法照亮前列腺癌放疗之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=400020e174d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939209, encodeId=3dab1939209b0, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO2021：精准医疗推动胃肠道癌症治疗的进展, objectType=article, longId=212454, objectId=b65621245468, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b65621245468, replyNumber=0, likeNumber=111, createdTime=2022-04-26, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b65621245468, moduleTitle=ASCO2021：精准医疗推动胃肠道癌症治疗的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b65621245468)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1939185, encodeId=6657193918590, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, objectTitle=ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）, objectType=article, longId=212197, objectId=060821219ee9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060821219ee9, replyNumber=0, likeNumber=0, createdTime=2021-11-07, rootId=0, userName=quxin068, userId=74808, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060821219ee9, moduleTitle=ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=060821219ee9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASC

2020-05-29

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期

2021-12-07

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望10 |乳腺癌研究概览（三阴性乳腺癌专栏）

2022-03-11

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021 :摘要概览与展望8 | 乳腺癌研究概览（男性乳腺癌专栏）

2021-11-25

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021:转移性乳腺癌专场口头摘要概览

2021-07-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效

2021-08-25

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：免疫治疗新进展！中国智造替雷利珠单抗多项研究成果亮相

2021-06-18

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望15 |乳腺癌研究概览（ER阳性乳腺癌专栏）

2022-05-03

quxin068 (审核中...)

前往app查看评论内容

#ASC#

2021ASCO| 第57届美国临床肿瘤学会年会在线开幕！

2021-12-09

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：天境生物公布其CD73抗体的1期临床研究成果，初步显示疗效信号

2021-08-08

quxin068 (审核中...)

前往app查看评论内容

#ASC#

Cardiovasc Intervent Radiol：使用支架进行腹腔镜结肠手术的肠吻合术可降低肠吻合时间

2021-10-09

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望21 |乳腺癌研究概览（HER2阳性乳腺癌专栏）

2021-11-16

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：皮肤癌免疫疗法新进展

2022-02-17

quxin068 (审核中...)

前往app查看评论内容

#ASC#

J Vasc Interv Radiol：两年研究结果表明DCB血管成形术对AVFs长期安全且有效

2020-12-19

quxin068 (审核中...)

前往app查看评论内容

#ASC#

BMC Cardiovascular Disorders：当一根长针扎进心脏 1 个月以上，人还活着！怎么取出针？——BMC期刊病例报道

2021-12-24

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）

2021-10-05

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：非小细胞肺癌专场--口头报告(01)

2022-05-22

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021: 神经肿瘤综述（上）

2022-01-23

zhaojie88 (审核中...)

前往app查看评论内容

#ASC#

ASCO GU 2021：Lu-177放射新疗法照亮前列腺癌放疗之路

2021-08-17

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO2021：精准医疗推动胃肠道癌症治疗的进展

2022-04-26

quxin068 (审核中...)

前往app查看评论内容

#ASC#

ASCO 2021：摘要概览与展望19 |乳腺癌研究概览（三阴性乳腺癌专栏）

2021-11-07

科室
- - 订阅+
  - 更多科室
工具
服务